A Prospective Study to Assess Vancomycin Serum Concentrations inPediatric Patients with Current Dosing Guidelines

Area of Science:

• Pediatric Pharmacology
• Infectious Diseases
• Clinical Pharmacy

Background:

• Rising bacterial resistance to vancomycin necessitates optimized dosing strategies.
• Adult vancomycin guidelines are often extrapolated to pediatric patients, despite lacking pediatric-specific data.
• Achieving therapeutic trough serum concentrations is crucial for effective vancomycin treatment.

Purpose of the Study:

• To evaluate the efficacy of current vancomycin dosing recommendations in achieving therapeutic trough serum concentrations in pediatric patients.
• To compare observed pediatric vancomycin serum levels with Infectious Disease Society of America (IDSA) 2011 guidelines for Methicillin-Resistant Staphylococcus Aureus (MRSA) infections.

Main Methods:

• Prospective observational, cross-sectional study in a university medical center.
• Analysis of laboratory data, vancomycin dosing, and serum concentrations in 50 pediatric patients receiving vancomycin.
• Trough serum levels were determined at steady state and compared to IDSA 2011 guidelines.

Main Results:

• 91% of patients on low-dose (40 mg/kg/day) and 85% on high-dose (60 mg/kg/day) vancomycin had sub-therapeutic serum concentrations.
• A significant majority of pediatric patients (73% and 69% in low and high dose groups, respectively) did not achieve recommended therapeutic vancomycin trough levels.
• Mean patient age was 5.47 ± 4.24 years with a creatinine clearance of 87.5 ± 31.25 mL/min.

Conclusions:

• Current vancomycin dosing regimens (40-60 mg/kg/day) are frequently inadequate for achieving therapeutic serum concentrations in pediatric patients.
• The findings suggest a need to re-evaluate and potentially revise current vancomycin dosing guidelines for pediatric populations.
• Optimizing pediatric vancomycin dosing is essential to combat MRSA infections effectively and mitigate resistance development.